Comparative Pharmacology
Head-to-head clinical analysis: GANTANOL versus RENOQUID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTANOL versus RENOQUID.
GANTANOL vs RENOQUID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydropteroate synthase, preventing folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate production. The combination produces sequential blockade of folate metabolism, leading to bactericidal activity.
RENOQUID is a combination of sulfamethoxazole, an intermediate-acting sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. It inhibits sequential steps in bacterial folic acid synthesis: sulfamethoxazole inhibits dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, leading to bactericidal activity.
800 mg orally every 12 hours for 5-7 days.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life: 8-12 hours in healthy adults; prolonged in renal impairment (up to 24-36 hours in CrCl <30 mL/min).
Terminal elimination half-life is 2.5 hours (range 2–3 hours) in patients with normal renal function. In renal impairment (CrCl <30 mL/min), half-life may extend to 8–12 hours.
Renal: 70% as unchanged drug; hepatic metabolism: 20% (glucuronidation); fecal: 10%.
Renal excretion accounts for approximately 70% of elimination, with 30% excreted unchanged in urine. Biliary/fecal excretion accounts for 30%, primarily as metabolites.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic